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Introduction


Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic that has placed an
unprecedented burden on intensive care services worldwide.



Identification of a reliable risk-stratification tool for COVID-19 patients is necessary for
appropriate resource allocation, selection of clinical management pathways, and guidance of
goals of care conversations with families and caregivers in the critical care setting.



The Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II scoring
system is one of several predictive models used to classify illness severity and estimate
mortality risk on admission to the intensive care unit (ICU).



Our retrospective study sought to evaluate the prognostic ability of the APACHE II score in
COVID-19 patients according to endpoints of mortality and length of stay (LOS) as well as
unfavorable clinical outcomes, including development of acute renal failure (ARF)
requiring continuous renal replacement therapy (CRRT) and acute venous thromboembolic
events (VTE).
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Methods


Study Design and Population:

A retrospective study using data from 59 United States Hospitals

395 patients (from 3,102) with valid data admitted in the ICU with COVID-19

January 2020 to May 2020.

Inclusion criteria: Ages18 and over.

Exclusion criteria: All patients with baseline end stage renal disease requiring dialysis
or history of venous thromboembolism on admission.



Outcomes and Exposure: Patients were categorized based on their initial APACHE II
score. The primary outcomes were mortality and LOS. The secondary outcome assessed
APACHE II scores in relation to development of ARF requiring CRRT or HD, and
development of acute VTE.



Statistical Analysis: Linear and logistic regression models were employed to evaluate
primary outcomes of mortality and LOS as well as secondary outcomes of VTE and ARF
requiring CRRT or HD.
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Table 1: Baseline Demographics:
Patient
Attributes:
Age:
Minimum
Mean (95%
Confidence
Interval)
Standard
Deviation
Median
Maximum
Race:
Asian
Black
Other/Unknown
White
Ethnicity:
Hispanic
Non-Hispanic
Other or
Declined to
Specify
Sex:
Female
Male

APACHE II
Score:
Greater Than
34

APACHE II
Score: 5-9

APACHE II
Score:
10-14

APACHE II
Score:
15-19

APACHE II
Score:
20-24

APACHE II
Score:
25-29

APACHE II
Score:
30-34

30

20

19

19

45.86
(37.66, 54.05)

54.17
(49.88, 58.46)

60.29
(55.37, 65.22)

68.74
(64.93, 72.55)

36
68.63
(65.18,
72.09)

23
71.05
(67.22,
74.87)

8.86

13.77

18.73

16.35

13.95

15.32

11.75

48
55

54.5
90

60.5
90

72
90

70
90

74.5
90

69.5
90

0 (0%)
4 (57.1%)
0 (0%)
3 (42.9%)

2 (4.8%)
5 (11.9%)
18 (42.9%)
17 (40.5%)

1 (1.7%)
11 (19%)
20 (34.5%)
26 (44.8%)

3 (4.1%)
11 (15.1%)
18 (24.7%)
41 (56.2%)

2 (3.1%)
10 (15.4%)
11 (16.9%)
42 (64.6%)

4 (6.3%)
20 (31.3%)
11 (17.2%)
29 (45.3%)

4 (4.7%)
21 (24.4%)
27 (31.4%)
34 (39.5%)

1 (14.3%)
6 (85.7%)

21 (50%)
20 (47.6%)

20 (34.5%)
35 (60.3%)

20 (27.4%)
51 (69.9%)

6 (9.2%)
59 (90.8%)

9 (14.1%)
51 (79.7%)

24 (27.9%)
59 (68.6%)

0 (0%)

1 (2.4%)

3 (5.2%)

2 (2.7%)

0 (%)

4 (6.3%)

3 (3.5%)

5 (71.4%)
2 (28.6%)

20 (47.6%)
22 (52.4%)

28 (48.3%)
30 (51.7%)

32 (43.8%)
41 (56.2%)

27 (41.5%)
38 (58.5%)

20 (31.3%)
44 (68.8%)

32 (37.2%)
54 (62.8%)
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39

69.33
(66.81, 71.85)

Table 1: Baseline Demographics:
Patient
Attributes:

APACHE II
Score: 5-9

AFib

0 (0.00%)

3 (7.14%)

7 (12.07%)

20 (27.40%)

21 (32.31%) 22 (34.38%)

37 (43.02%)

HTN

6 (85.71%)

21 (50.00%)

29 (50.00%)

34 (46.58%)

22 (33.85%) 20 (31.25%)

25 (29.07%)

DMII

3 (42.86%)

13 (30.95%)

18 (31.03%)

22 (30.14%)

26 (40.00%) 22 (34.38%)

32 (37.21%)

CAD

1 (14.29%)

3 (7.14%)

8 (13.79%)

17 (23.29%)

20 (30.77%) 18 (28.13%)

20 (23.26%)

COPD

0 (0.00%)

0 (0.00%)

1 (1.72%)

0 (0.00%)

Heart Failure
(Systolic or
Diastolic)

0 (0.00%)

3 (7.14%)

7 (12.07%)

17 (23.29%)

11 (16.92%) 13 (20.31%)

19 (22.09%)

CKD (I-IV)

1 (14.29%)

0 (0.00%)

8 (13.79%)

15 (20.55%)

20 (30.77%) 26 (40.63%)

37 (43.02%)

0 (0.00%)

1 (2.38%)

0 (0.00%)

1 (1.37%)

0 (0.00%)

2 (3.13%)

2 (2.33%)

0 (0.00%)

1 (2.38%)

2 (3.45%)

1 (1.37%)

2 (3.08%)

2 (3.13%)

2 (2.33%)

0 (0.00%)

0 (0.00%)

1 (1.72%)

1 (1.37%)

3 (4.62%)

3 (4.69%)

2 (2.33%)

Alcohol
Abuse
Tobacco
Abuse

PVD
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APACHE II
Score:
15-19

APACHE II
Score:
20-24

APACHE
II Score:
25-29

3 (4.62%)

APACHE
II Score:
30-34

APACHE II
Score:
Greater Than
34

APACHE II
Score:
10-14

0 (0.00%)

1 (1.16%)

Primary Outcomes


Among the 395 patients enrolled, percent mortality and mean length of stay were 37.0%
and 12.92 days, respectively.



Mortality: A statistically significant increase in odds of mortality was noted with every
additional point increase in APACHE II score from a baseline of zero, where odds of
mortality increased by 12% (95% CI (0.08, 0.14); p < 0.001).




A sub analysis using a chi-squared test, revealed a statistically significant relationship
between patients with CKD and heart failure with having increased mortality (p <
0.001).

Length of Stay: For every additional point increase in APACHE II score from a baseline
of zero, average LOS increased by 0.2 days (p value < 0.001).
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Figure 1: APACHE II Score and Mortality:
Relationship between APACHE II Score and
mortality, while controlling for race, ethnicity, sex,
and administration of anticoagulation.
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Preexisting Diagnosis of Heart Failure
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Figure 3: Demonstrates the proportion of patients with
COVID-19 disease that expired according to presence or
absence of preexisting chronic kidney disease (Stage I
through IV).
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Figure 2: Demonstrates the proportion of patients with
COVID-19 disease that expired according to presence or
absence of preexisting systolic or diastolic congestive heart
failure.
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CKD

Not Expired

Secondary Outcomes


ARF requiring CRRT/HD: 14.43% of total sample population required CRRT/HD. For
every additional point increase in APACHE II score, odds of requiring CRRT or HD
increased by 10% on average (95% CI (1.06, 1.15); p value < 0.001).

Patients with an indicated race of “black” had 3.41 times higher odds of requiring
CRRT/HD (95% CI (1.53, 7.77); p = 0.003), when compared to race “white”.

Patients with a history of atrial fibrillation had 2.02 times higher odds of requiring
CRRT/HD than those without a history of atrial fibrillation (95% CI (1.01, 4.07), p =
0.05).



Development of VTE: For every additional point increase in the APACHE II score, there
was a corresponding increase in odds of VTE by 19% (95% CI (1.14, 1.24); p value <
0.001).

Patients with a history of hypertension (HTN) had 2.03 times higher odds of
developing acute VTE, than those without (95% CI (1.03, 4.15); p = 0.04).

Patients with a history of CKD had 10.46 times higher odds of developing acute VTE
than patients without (95% CI (4.42, 27.64); p = 0.001).
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Table 2: Summary of Primary and Secondary Outcomes
Primary endpoints evaluated included mortality and mean length of stay.
Secondary endpoints included VTE events and ARF requiring CRRT or HD.

APACHE II
Score: 5-9

APACHE II
Score:
10-14

APACHE II
Score:
15-19

APACHE II
Score:
20-24

APACHE II
Score:
25-29

APACHE II
Score:
30-34

APACHE II
Score:
Greater Than
34

Mortality

1 (14.3%)

0 (0%)

8 (13.8%)

20 (27.4%)

26 (40.0%)

36 (56.3%)

55 (64.0%)

Mean Length of
Stay

8.86

11.30

10.10

11.90

14.10

12.30

16.40

Venous
Thromboembolis
m

3 (42.86%)

6 (14.29%)

14 (24.14%)

39 (53.42%)

46 (70.77%)

55 (85.94%)

83 (96.51%)

CRRT or HD

0 (0.00% )

0 (0.00% )

1 (1.72% )

5 (6.85% )

8 (12.31% )

14 (21.9% )

29 (33.7% )
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Discussion
Mortality in COVID-19 Disease:
Mortality Estimates:
 Initial mortality estimates exceeded ninety-percent in COVID-19 patients undergoing invasive
mechanical ventilation.
 Note: This may have been reflective of resource limitations in the pandemic setting as well as
the rapid progression of COVID-19 itself.
 A recent systematic review and meta-analysis of 24 observational studies, including 10,150 patients
from centers across Asia, Europe, and North America, reported a pooled intensive care unit
mortality rate of upwards of forty-percent1.
 This remains disproportionately higher than the mortality rate of other viral pneumonias
admitted to the ICU.
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Discussion (Continued)
Acute Physiology and Chronic Health Evaluation Score as a Predictor of In Hospital Mortality in
Patients with Coronavirus Disease 20192:
Study Design: Single-center, retrospective study based in Wuhan, China (Hubei Province).
Objective: Sought to classify illness-severity and estimate mortality-risk in patients with COVID-19
using 3 existing scoring systems:
1. Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II Score
2. Sequential Organ Failure Assessment (SOFA) Score
3. Confusion, Urea, Respiratory Rate, Blood Pressure, and Age (CURB-65) Score
Results: Demonstrated that the APACHE II score is an effective predictive model of mortality in
COVID-19 patients.
This is as compared to the SOFA and CURB-65 scores.
Note: This is likely attributable to the fact that the APACHE II score accounts for both age and
presence of existing comorbidities, which appear to be independent predictors of disease severity and
mortality-risk in COVID-19 alone, and the SOFA score, which fails to account for either age or
presence of comorbidities.
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Discussion (Continued)
Primary Endpoints:
 Mortality: The APACHE II score was positively associated with mortality in COVID-19 disease.
For every additional point obtained above zero, mortality increased by twelve percent on average.
 Length of Stay: For every additional point above zero in the APACHE II score, there was a
corresponding increase in length of stay by approximately 0.20 days.
 Note: Abovementioned identified via logistic regression analysis, controlling for
demographic variables including race, ethnicity, and sex.
Predictors of mortality: Increased mortality was observed in heart failure and chronic kidney
disease patients with COVID-19.
*Note: This was not statistically significant in the initial logistic regression model; although
subsequent univariate analysis (via Chi-square testing) demonstrated statistical significance of
mortality in this subset of the patient population.

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare
affiliated entity. The views expressed in this publication represent those of the author(s) and do
not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.

Discussion (Continued)
Secondary Endpoints:
 Acute Kidney Injury Requiring Renal Replacement Therapy: Identified a statistically
significant association between a higher APACHE II score and development of acute kidney
injury requiring subsequent initiation of renal replacement therapy (e.g. CRRT or
Hemodialysis).
 Odds of initiation of CRRT or HD increased by ten-percent for every additional point
obtained in the APACHE II score above zero.
 Venous Thromboembolic Events: The APACHE II score was positively associated with
venous thromboembolic events (e.g. DVT and PE).
 For every additional point obtained in the APACHE II score, there was nineteen-percent
increase in odds of VTE.
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Strengths and Limitations
Strength: This is a multicenter retrospective study that evaluated a diverse patient population
across 59 unique hospitals in the United States according to specific endpoints not previously
studied in COVID-19 disease.
Limitations:
 Sample size.
 Patients without valid or complete documentation of vital signs, Glasgow Coma Scale scores,
or laboratory data on admission to the ICU were strictly excluded, given inability to accurately
calculate corresponding APACHE II scores.
 Marked variability in documentation of ICD-10 codes.
 Inability to differentiate between patients receiving prophylactic versus therapeutically dosed
anticoagulation in our data sample, inhibiting our ability to evaluate the role of anticoagulation
therapy with respect to our prespecified outcomes.
 Retrospective study: View observational data with caution, in view of the fact that our findings
may have been influenced by unmeasured or unidentified confounders.
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Conclusion
 We propose that the APACHE II score could be an effective predictive model for unfavorable
clinical outcomes in COVID-19 disease.

 Accurate prediction of mortality as well as disease-related complications with this riskstratification tool may facilitate appropriate allocation of resources and direct goals of care
conversations with family and caregivers on admission to the ICU.
 Further investigation of the impacts of intervention on mortality, length of stay, and other
adverse outcomes is warranted, given these findings.
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